Text this: Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

 _    _     _____               _____   __    __  
| |  | ||  |  ___||     ___    |  ___|| \ \\ / // 
| |/\| ||  | ||__      /   ||  | ||__    \ \/ //  
|  /\  ||  | ||__     | [] ||  | ||__     \  //   
|_// \_||  |_____||    \__ ||  |_____||    \//    
`-`   `-`  `-----`      -|_||  `-----`      `     
                         `-`